ANONYMOUS: "Bioavailability and Effect of Food on TAK-385 Tablet Formulations in Healthy Participants - Study Results - ClinicalTrials.gov", 25 July 2016 (2016-07-25), XP055459565, Retrieved from the Internet <URL:https://www.clinicaltrials.gov/ct2/show/results/NCT02396147?term=relugolix&rank=9> [retrieved on 20180315] (B1)

ANONYMOUS: "History of Changes for Study: NCT02135445 - Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer", 1 March 2017 (2017-03-01), Retrieved from the Internet <URL:https://www.clinicaltrials.gov/ct2/history/NCT02135445?V_8=View#StudyPageTop> [retrieved on 20210223] (B1)

ANONYMOUS: "NCT02083185 on 2016_06_02: ClinicalTrials.gov Archive", 2 June 2016 (2016-06-02), XP055459572, Retrieved from the Internet <URL:https://clinicaltrials.gov/archive/NCT02083185/2016_06_02> [retrieved on 20180315] (B1)

ANONYMOUS: "NCT02135445 on 2016_06_02: ClinicalTrials.gov Archive", 2 June 2016 (2016-06-02), XP055459576, Retrieved from the Internet <URL:https://clinicaltrials.gov/archive/NCT02135445/2016_06_02> [retrieved on 20180315] (B1)

CA-A1- 2 978 223 (B1)

SHORE NEAL D ET AL: "PD28-01 TESTOSTERONE LOWERING, PSA RESPONSE AND QUALITY OF LIFE IN PATIENTS WITH ADVANCED HORMONE SENSITIVE PROSTATE CANCER RECEIVING TAK-385, AN ORAL GNRH ANTAGONIST: PHASE 2 INTERIM ANALYSIS", JOURNAL OF UROLOGY, vol. 195, no. 4, 8 May 2016 (2016-05-08), XP029476663, ISSN: 0022-5347, DOI: 10.1016/J.JURO.2016.02.388 (B1)

KAZUHIRO MIWA ET AL: "Discovery of 1-{4-[1-(2,6-Difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3- d ]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a Potent, Orally Active, Non-Peptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor", JOURNAL OF MEDICINAL CHEMISTRY, vol. 54, no. 14, 28 July 2011 (2011-07-28), pages 4998 - 5012, XP055012890, ISSN: 0022-2623, DOI: 10.1021/jm200216q (B1)

N SHORE ET AL: "S474 Abstracts 2502 ORAL TAK-385, an oral GnRH antagonist: efficacy and safety results from a randomized phase 2 trial in prostate cancer patients (pts)", 1 September 2015 (2015-09-01), XP055459562, Retrieved from the Internet <URL:http://www.ejcancer.com/article/S0959-8049(16)31324-7/pdf> [retrieved on 20180315] (B1)

NAKATA DAISUKE ET AL: "Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: Studies in human GnRH receptor knock", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 723, 11 December 2013 (2013-12-11), pages 167 - 174, XP028607987, ISSN: 0014-2999, DOI: 10.1016/J.EJPHAR.2013.12.001 (B1)

SAAD FRED ET AL: "Second interim analysis (IA2) results from a phase II trial of TAK-385, an oral GnRH antagonist, in prostate cancer patients (pts). | Journal of Clinical Oncology", JOURNAL OF CLINICAL ONCOLOGY, 10 January 2016 (2016-01-10), XP055778964, Retrieved from the Internet <URL:https://ascopubs.org/doi/abs/10.1200/jco.2016.34.2_suppl.200> [retrieved on 20210223] (B1)

DAVID B. MACLEAN ET AL: "Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 100, no. 12, 1 December 2015 (2015-12-01), US, pages 4579 - 4587, XP055459555, ISSN: 0021-972X, DOI: 10.1210/jc.2015-2770 (B1)